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Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are considered to be part of a spectrum. Clinically, FTD patients present with dementia frequently characterized by behavioral and speech problems. ALS patients exhibit alterations of voluntary movements caused by degeneration of motor neurons. Both syndromes can be present within the same family or even in the same person. The genetic findings for both diseases also support the existence of a continuum, with mutations in the same genes being found in patients with FTD, ALS, or FTD/ALS.
The figure on the left represents the distribution of genes according to their associated phenotype and mutation frequency in familial cases (this can vary between cohorts or populations).
Some cases of mutations in genes represented in the extremes of the graph (associated with either ALS or FTD) have also been described as associated with the other clinical phenotypes. For example, mutations in TARDBP that are the cause of ALS have, in rare occasions, been described in cases presenting with FTD. The genetic evidence for these associations is weak (mainly lacking segregation of the variants with the phenotypes or strong evidence of pathogenicity), and for these reasons, such genes are represented as the extremes of the FTD-ALS continuum.
Genetic ALS is usually not only associated with motor systems degeneration but also, very frequently, occurs in combination with degenerative processes like parkinsonism or ataxia. In fact, very few ALS genes have been associated with a strict motor-only phenotype, and genes commonly associated with other diseases have sometimes been found to be the cause of ALS. This was the case for FIG4 and SPAST mutations that have been originally associated with Charcot-Marie-Tooth neuropathy type 4J (CMT4J) and autosomal-dominant spastic paraplegia-4 (SPG4), respectively, and have been subsequently found to be mutated in ALS cases.
These overlaps between different phenotypes and genes found to be mutated either in ALS with additional features or in other diseases and ALS are represented in the right panel.
One FTD gene (PRKAR1B) and several ALS genes (ARHGEF28, for example) have been, so far, only reported in a single family (with different levels of segregation) or have not yet been independently replicated. PRKAR1B was identified in an FTD-like family with a syndrome considered to be novel. The family presented dementia and/or parkinsonism in 12 affected individuals and a unique neuropathology displaying abundant neuronal inclusions by hematoxylin and eosin staining throughout the brain with immunoreactivity for intermediate filaments. Some ALS genes have conflicting results with variants described in controls and uncertain pathogenicity attributed to different mutations (ANG, for example).
Several genes implicated in FTD and ALS have possible functions within the same biological pathways such as autophagy and the lysosomal pathway, maintenance of neuronal cytoskeleton, and DNA/RNA metabolism. In some cases, genes also share similar domains like the RNA binding genes with prion-like domains HNRNPA1, HNRNPA2B1, TARDBP, FUS, TAF15, and EWSR1. In fact, TAF15 and EWSR1 were screened for the identification of variants because of their commonalities with FUS and TARDBP. In both genes, variants were found in patients with sporadic ALS, and weak familial segregation has only been demonstrated for TAF15.
The use of next-generation sequencing technologies has recently allowed the identification of rare variants in TUBA4A to be associated with ALS, and the analyses of de novo mutations in sporadic ALS trios have identified mutations in SS18L1. Again, the approaches used did not allow for segregation analyses and, for this reason, even though the variants were associated with familial ALS, the genes are not included as a Mendelian gene for ALS in the table.
Other genes have been reported as susceptibility or modifiers of FTD and/or ALS with different levels of evidence. These include, in addition to the ones represented in the The loci identified by genome-wide association studies are named according to the closest gene to the most significant hit at each locus. It is possible that the gene involved in FTD and/or ALS is not the closest but is in linkage disequilibrium with the true hit. This has been recently shown to be the case for UNC13A, where KCNN1 (a nearby gene) was implicated by eQTL analysis.
An asterisk (*) indicates genes for which mutations may present additional phenotypes or be the cause of different clinical syndromes. For example, loss-of-function heterozygous mutations in GRN cause FTD, whereas homozygous mutations in the same gene have recently been reported to cause neuronal ceroid lipofuscinosis-11 (CLN11); VCP mutations are known to cause ALS with or without FTD and inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD).
AbbreviAtions
CMT neuropathy, Charcot-Marie-Tooth neuropathy; POAG, primary open angle glaucoma; SMA/PMA, spinal muscular atrophy/progressive muscular atrophy; AOA2, Ataxia with oculomotor apraxia type 2.
